GCP
GALT icon

GSA Capital Partners’s Galectin Therapeutics GALT Stock Holding History

GSA Capital Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$597K Buy
128,664
+57,239
+80% +$148K 0.04% 875
2026
Q1 		$199K Sell
71,425
-30,541
-30% -$92.9K 0.01% 1459
2025
Q4 		$424K Buy
101,966
+14,872
+17% +$78.3K 0.04% 928
2025
Q3 		$369K Buy
+87,094
New +$328K 0.03% 1071
2025
Q2 		– Sell
-66,396
Closed -$81K – 1882
2025
Q1 		$81K Buy
66,396
+44,862
+208% +$62.9K 0.01% 1523
2024
Q4 		$28K Buy
+21,534
New +$51.6K ﹤0.01% 1551
2019
Q2 		– Sell
-56,915
Closed -$291K – 1537
2019
Q1 		$291K Buy
+56,915
New +$273K 0.03% 1005

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSA Capital Partners's GALT Position: Q2 2026 in Review

GSA Capital Partners increased its Galectin Therapeutics (GALT) stake by 80% in Q2 2026, buying an estimated $148K and bringing the position to 128,664 shares worth $597K. The position accounts for 0.04% of the portfolio, ranked #875.

GSA Capital Partners first reported a position in GALT in Q1 2019 and has held it in 7 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • GSA Capital Partners held 128,664 shares of Galectin Therapeutics worth $597K as of Q2 2026.
  • GSA Capital Partners bought 57,239 Galectin Therapeutics shares in Q2 2026, an estimated $148K.
  • Galectin Therapeutics made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #875 holding.
  • GSA Capital Partners first reported a position in Galectin Therapeutics in Q1 2019 and has held it in 7 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.